Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Roku

Snap

Don't count these stocks out over the long haul.

3 Top Growth Stocks to Buy That Were Down More Than 15% in March

Catalent

Catalent Inc (NYSE: CTLT) is reportedly expanding its U.S. production of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Moderna fill its vaccine in vials for shipment.

Catalent To Boost Output Of Finished Vials For Moderna's COVID-19 Shot: WSJ

Catalent Inc. , a contract drug manufacturer, is expanding U.S. production of the COVID-19 vaccine developed by Moderna Inc. and will nearly double production at its Bloomington, Ind. plant to about 400 vials a minute in April, the Wall Street Journal reported Tuesday, citing people familiar with the matter.

Contract drug maker Catalent to double production of Moderna COVID vaccine: WSJ

The FDA approved new vials from Moderna Inc (NASDAQ: MRNA) that can contain up to 15 doses each, compared with the designed to hold ten doses. Additionally, regulators said providers could safely extract up to 11 doses from the original 10-dose vials.

FDA Authorizes Two Vial Presentations For Moderna's COVID-19 Vaccine

Johnson & Johnson

Pfizer

They're working to target coronavirus strains of the future.

These 3 Vaccine Stocks May Be Post-Pandemic Winners

This might break Moderna out of the doldrums.

Here's the Next Catalyst for Moderna Shares

We're looking at 15% of the U.S. population.

This Could Be a New Billion-Dollar Market for Moderna

A key member of the Moderna team is saying goodbye.

Should Investors Worry About This Announcement From Moderna?

An update to the Moderna Covid-19 vaccine's emergency use authorization could make it easier to get more doses into more people.

FDA Eases Storage Restrictions for Moderna's Covid-19 Vaccine

The U.S. is on course to surpass 100 million people who have received at least one dose of the vaccine by the end of Friday.

Nearly 100 Million Americans Have Received A Covid-19 Vaccine As FDA Allows Moderna To Boost Doses Per Vial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna provides storage update & announces the U.S. FDA authorizes up to 15-doses per vial of its COVID-19 vaccine.

Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine

PROVIDENCE, R.I., March 31, 2021 /PRNewswire/ -- Ximedica today announced a partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program.

Ximedica announces partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines

There's a surprisingly good case to be made.

Why Moderna Could Actually Be a Value Stock

iBio

Novavax

Ocugen, Inc.

VanEck Vectors Pharmaceutical ETF

Sorrento Therapeutics Inc

AstraZeneca

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared first on InvestorPlace.

7 Pharmaceutical Stocks That Could Get a Covid Hangover

Researchers started a clinical trial to evaluate the biotech's new coronavirus vaccine candidate.

Why Moderna Stock Soared Today

The National Institutes of Health has started testing a new coronavirus vaccine from Moderna designed to protect against a problematic variant first found in South Africa.

U.S. begins testing Moderna's Covid vaccine booster shots for variant from South Africa

President Biden is contemplating suspending intellectual property rights for COVID-19 vaccines.

Suspending Vaccine IP Rights Could Sink Moderna, Novavax

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to host second annual virtual Vaccines Day on April 14, 2021.

Moderna to Host Second Annual Virtual Vaccines Day on April 14, 2021

Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.

Moderna ETFs to Gain on Positive 'Real-World' Study Data

More than two-thirds of those jabs have already been administered.

Moderna Has Shipped 100 Million Coronavirus Vaccine Doses to the U.S.

Pfizer and Moderna vaccines 80% effective at preventing COVID-19 after one shot, CDC says

Covid-19 vaccine stocks tumbled Monday despite a real-world study showing Moderna's and Pfizer's two-dose coronavirus vaccines are 80% effective after the first dose. The post CDC Head Expresses Sense Of 'Impending Doom' Despite New Vaccine Study appeared first on Investor's Business Daily.

CDC Head Expresses Sense Of 'Impending Doom' Despite New Vaccine Study

The study shows the vaccines prevent all coronavirus infections, not just symptomatic ones.

CDC: Pfizer And Moderna Vaccines Could Significantly Cut Down On Coronavirus Transmission

The two-dose COVID-19 vaccines from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) lower the risk for infection by up to 90%, according to data released by the U.S. Centers for Disease Control and Prevention. The study was released in Morbidity and Mortality Weekly Report, an online journal published by the Centers for Disease Control and Prevention.

CDC New Study Shows Pfizer, Moderna COVID-19 Shots 90% Effective Against Infection In Real-World Setting

A single dose of Pfizer or Moderna's Covid-19 vaccines was 80% effective in preventing infections, according to a new CDC study.

News for Moderna Stock (MRNA)